A BRIGHTER FUTURE IS ON THE WAY

PLACENTIA, CA / NEWSFILE / August 11, 2026

Today, InVitro International (OTCQB: IVRO) reported FY ’26 Q3 sales of $117,760, off 24.1% from the same period in FY ’25. YTD sales of $567,200, reversing 2Q trends, are now 15.9% below the same period in FY ’25. Net income for IVRO's Q3 was $8,476, off 81.7% from last year's same period. Three quarters FY '26 net income totals $36,636, 61.7% below FY '25's first three quarters.

CEO & Chairman, W. Richard Ulmer stated: "IVRO is disappointed by our recent 3 months sales. In examining quarters in recent years, we did not find 3 consecutive months such as these. Therefore, IVRO looks forward to a strong finish to FY '26. We are enthused to read that FDA, EPA and other U.S. Government Regulatory Agencies recently stated their hope for more NON-animal tests done in future submissions, more humane treatment of animals."

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology driven provider of non-animal testing methods. The Company’s testing technologies are designed to produce Regulatory Agencies’ approved data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO’s technology is commercialized globally through test kits and partner laboratory services.

Company Contact:
W. Richard Ulmer
Chairman and Chief Executive Officer
(800)246-8487
invitro@invitrointl.com